Effect of Repetitive Glucose Spike and Hypoglycaemia on Atherosclerosis and Death Rate in Apo E-Deficient Mice

Kenichi Nakajima, 1 Tomoya Mita, 1,2 Yusuke Osonoi, 1 Kosuke Azuma, 1 Toshiyuki Takasu, 3 Yoshio Fujitani, 1 and Hirotaka Watada 1,2,4,5

1 Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
2 Center for Molecular Diabetology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
3 Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan
4 Center for Therapeutic Innovations in Diabetes, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
5 Sportology Center, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

Correspondence should be addressed to Tomoya Mita; tom-m@juntendo.ac.jp

Received 12 June 2015; Revised 31 July 2015; Accepted 9 August 2015

Academic Editor: Marco Bugliani

Copyright © 2015 Kenichi Nakajima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Epidemiological data suggest that postprandial hyperglycaemia and hypoglycaemia are potential risk factors for cardiovascular disease. However, the effects of repetitive postprandial glucose spikes, repetitive hypoglycaemia, and their combination on the progression of atherosclerosis remain largely unknown. The present study investigated the effects of rapid rises and falls in glucose, and their combination, on the progression of atherosclerosis in apo E-deficient mice. In this study, apo E-deficient mice with forced oral administration of glucose twice daily for 15 weeks were used as a model of repetitive postprandial glucose spikes, and apo E-deficient mice given an intraperitoneal injection of insulin once a week for 15 weeks were used as a model of repetitive hypoglycaemia. In addition, we established a model of both repetitive postprandial glucose spikes and hypoglycaemia by combining the above interventions. Atherosclerosis was evaluated in all mice by oil red O staining. Administration of ipragliflozin, a selective inhibitor of sodium-glucose cotransporter 2, in the mouse model of repetitive glucose spikes inhibited the progression of atherosclerosis, whereas long-term repetitive glucose spikes, repetitive hypoglycaemia, and their combination had no significant impact on atherosclerosis. However, repetitive hypoglycaemia was associated with poor survival rate. The results showed that repetitive hypoglycaemia reduces the survival rate without associated progression of atherosclerosis in apo E-deficient mice.

1. Introduction

Patients with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD), which is also the most frequent cause of death in these patients. Thus, one of the main goals of management of T2DM is to reduce the onset of CVD.

While hyperglycaemia is presumed to play a significant role in the progression of atherosclerosis, several epidemiological studies have suggested that postprandial hyperglycaemia per se is an independent risk factor for developing CVD [1, 2]. In this regard, we demonstrated previously that temporary hyperglycaemia induces monocyte adhesion to endothelial cells in the aorta of rats [3] and that repetitive glucose spikes enhance atherosclerotic lesions in apolipoprotein (apo) E-deficient mice [4]. In the second of these studies, the progression of atherosclerosis was attenuated by administration of an α-glucosidase inhibitor with the associated reduced amplitude of glucose spikes [4]. Furthermore, an in vitro study showed that intermittent treatment of high blood glucose levels increases apoptosis of endothelial cells by increasing oxidative stress [5]. Similarly, T2DM patients with glucose spikes had high oxidative stress level and endothelial dysfunction [6]. Although data on this topic
remain controversial [7], the studies cited above suggest that glucose fluctuation could adversely affect the progression of atherosclerosis.

On the other hand, most clinical studies showed that reducing HbA1c levels had no beneficial effects on the incidence of CVD [8–10], possibly due to attenuation of the beneficial glucose-lowering effect by increased incidence of hypoglycaemic events. Indeed, a recent study reported that hypoglycaemia was associated with increased risk of cardiovascular events and all-cause mortality in insulin-treated patients with type 1 diabetes mellitus and T2DM [11]. While it is well known that hypoglycaemia affects cognition, mood, and consciousness, it has also profound effects on blood constituents [12, 13], inflammatory cytokine levels [14, 15], and coagulation and fibrinolysis factors [16, 17], all of which could potentially enhance the progression of atherosclerosis. Indeed, we found that repetitive hypoglycaemia induced monocyte adhesion to endothelial cells in the aorta [18] and enhanced neointima formation after vascular injury [19] in nonobese diabetic Goto-Kakizaki (GK) rats through a surge of sympathetic nerve activity.

The above studies investigated the effect of either rapid rises or falls in glucose levels on monocyte adhesion to endothelial cells or neointima formation after vascular injury. On the other hand, no convincing in vivo data exist about the combined effect of downward and upward spikes in circulating glucose using a mouse model of atherosclerosis. The present study investigated the effects of rapid rises and falls in glucose, and the combination thereof, on the progression of atherosclerosis in apo E-deficient mice.

2. Materials and Methods

2.1. Animal Experiments. The study protocol was reviewed and approved by the Animal Care and Use Committee of Jun- tungo University. Eight-week-old male apo E-deficient mice were purchased from Jackson Laboratory or Charles River Japan (Yokohama, Japan) and housed in specific pathogen-free barrier facilities at the Institute of Nihon Bioresearch Inc. (Gifu, Japan). Mice were maintained under a 12 h light/dark cycle and fed a standard rodent diet (CRF-1, Lot numbers 131008, 131203, and 140206, Oriental Yeast Co.). At 12 weeks of age, the apo E-deficient mice were divided into five treatment groups matched by body weight (BW) and plasma glucose level (Figure 1). Mice of the control group (n = 22) were provided with water by oral gavage twice a day (9:00 AM and 4:00 PM) and received intraperitoneal injections of 10 mL/kg saline in the morning once a week. Mice of the glucose group (n = 22) were provided with glucose (2.0 g/kg) by oral gavage twice a day and received intraperitoneal injections of 10 mL/kg saline once a week. Mice of the insulin group (n = 22) were provided with water by oral gavage twice a day and received intraperitoneal injections of 8 IU/kg insulin once a week. Mice of the glucose plus insulin group (n = 22) were provided with glucose (2.0 g/kg) by oral gavage twice a day and received intraperitoneal injections of 8 IU/kg insulin once a week. Food intake and BW were measured weekly. At days 18 and 102, we recorded changes in plasma glucose and insulin concentrations in almost half of the mice after oral administration of saline or glucose or ipragliflozin while feeding normally. We also monitored changes in plasma glucose concentrations in almost half the remaining mice after insulin or saline injection at day 22 and day 92 while feeding normally. In those experiments, the mice in each group were further divided into two groups (n = 11, each) to reduce the burden of frequent blood sampling for measuring plasma glucose and insulin. All mice in all groups were sacrificed at 27 weeks of age to evaluate atherosclerotic changes.

2.2. Blood Testing. Plasma glucose levels were measured spectrophotometrically (U-3010, Hitachi High-Technologies Corporation), and plasma insulin levels (immunoreactive insulin, IRI) were measured by ELISA (Ultra Sensitive “PLUS” Mouse Insulin ELISA Kit, Morinaga Institute of Biological Science, Inc.) using a microplate reader (Powarscan HT, DS Pharma Biomedical Co.). Total cholesterol, high-density-lipoprotein cholesterol, low-density-lipoprotein cholesterol, and triglycerides were also measured with automated chemistry analyzer (AU 400, Beckman Coulter Biomedical K.K.) by enzyme method, direct measuring method, enzymatic assay, or glycerol blanking method, respectively. The levels of various serum cytokines, including tumour necrosis factor-α, interleukin-1β, and interleukin-6, were measured using a Multiplex kit (Merck Millipore) that uses nonmagnetic polystyrene bead-based luminescent 200xPONENT technology (Merck Millipore).

2.3. Immunohistochemistry. After sacrifice with intraperitoneal sodium pentobarbital (1 mg/kg; Abbott Laboratories), the heart and aorta of all mice were flushed with normal saline followed by 10% buffered formalin, as described previously [20–22]. The aorta was excised from the root to the abdominal area, and then the connective and adipose tissues were removed from the aorta manually. For quantitative analysis of atherosclerotic lesions in the aortic sinus, the hearts were cut in half and the top half was embedded in optimal cutting temperature compound. Then, 4 μm thick cross sections at 50 μm intervals were prepared with a cryostat. Six consecutive sections were also taken sequentially from just above the aortic valve throughout the aortic sinus and allowed to dry at room temperature for 30 minutes, before staining with oil red O. In addition, whole aortas were also stained with oil red O. Histological images were analyzed by ImagePro Plus software. The lesion areas were calculated by dividing the oil red O-positive area by the total luminal area of the aorta.

2.4. Statistical Analysis. Results are presented as mean ± SEM of available data from surviving mice. Differences of laboratory blood test values among groups were examined by the Tukey post hoc or Student’s t-test. Differences of histopathological parameters among groups were examined by Dunnett’s multiple test or Student’s t-test. The cumulative
Figure 1: Experimental protocol. Mice of the control group (n = 22) were provided with water by oral gavage twice a day (9:00 AM and 4:00 PM) and received intraperitoneal injections of 10 mL/kg saline in the morning once a week. Mice of the glucose group (n = 22) were provided with glucose (2.0 g/kg) by oral gavage twice a day and received intraperitoneal injections of 10 mL/kg saline once a week. Mice of the glucose (2.0 g/kg) plus ipragliflozin group (n = 22) were provided with glucose (2.0 g/kg) twice a day and ipragliflozin (3 mg/kg) once a day by oral gavage and received intraperitoneal injections of 10 mL/kg saline once a week. Mice of the insulin group (n = 22) were provided with water by oral gavage twice a day and received intraperitoneal injections of 8 IU/kg insulin once a week. Mice of the glucose plus insulin group (n = 22) were provided with glucose (2.0 g/kg) by oral gavage twice a day and received intraperitoneal injections of 8 IU/kg insulin once a week.

Survival rates were compared by the log-rank test. A P value < 0.05 was considered significant. All tests were performed using the SAS software (SAS Institute, Japan).

3. Results

After 15 weeks of intervention, BW, food consumption, and lipid parameters were comparable among the five groups (Table 1). Table 2 shows plasma glucose concentrations after oral administration of saline or glucose with or without ipragliflozin at 18 days and 102 days. As expected, the glucose group exhibited a significant increase in plasma glucose after the administration of glucose twice a day. In addition, the glucose plus insulin group showed a similarly acute rise in plasma glucose levels to those of the glucose group. Plasma glucose levels were comparable between the control group and the insulin group. Unexpectedly, the use of ipragliflozin significantly increased glucose levels before the first administration of glucose and caused only a modest decrease in plasma glucose levels after glucose administration.

Table 3 shows plasma insulin concentrations after oral administration of saline or glucose with or without ipragliflozin at 18 and 102 days. Increases in plasma insulin concentration in correspondence with glucose spikes were continuously observed in the glucose group, the glucose plus ipragliflozin group, and the glucose plus insulin group. Interestingly, glucose-induced insulin secretion tended to diminish by concomitant use of ipragliflozin.

At days 22 and 92, we evaluated the effects of insulin injection on plasma glucose levels (Table 4). As expected, insulin injection induced hypoglycaemia both in the insulin group and in the glucose plus insulin group, but not in the other three groups. However, mice of the glucose plus insulin group showed only modestly higher glucose levels at 92 days after repeated administration, compared with those measured at day 22. On the other hand, serum cytokine levels were not different among the groups (Table 1).

Figure 2 shows the Kaplan-Meier curves, representing the survival rate of each group. Intriguingly, the survival rate was significantly lower in the insulin group compared with the other groups. To investigate the progression of atherosclerosis, we evaluated the oil red O-positive areas at the aortic valve level (Figure 3). The areas of oil red O staining of the aortic sinus were comparable among groups, although those of the glucose and glucose plus insulin groups tended to be slightly larger (Figure 3(a)). On the other hand, the oil red O-positive areas relative to the entire aorta of the glucose plus
**Table 1: Body weight, food intake, and laboratory data for each group after 15 weeks’ administration.**

|                         | Control group (n = 21) | Glucose group (n = 21) | Glucose + ipragliflozin group (n = 22) | Insulin group (n = 17) | Glucose + insulin group (n = 20) |
|-------------------------|------------------------|------------------------|---------------------------------------|------------------------|----------------------------------|
| Body weight (g)         | 25.6 ± 0.3             | 25.7 ± 0.3             | 25.3 ± 0.3                            | 25.8 ± 0.5             | 25.5 ± 0.4                       |
| Food intake (g/day)     | 3.1 ± 0.1              | 3.0 ± 0.1              | 3.0 ± 0.1                             | 3.0 ± 0.1              | 2.9 ± 0.1                        |
| HbA1c (%)               | 3.8 ± 0.0              | 3.8 ± 0.1              | 3.8 ± 0.0                             | 3.8 ± 0.0              | 3.8 ± 0.0                        |
| Total cholesterol (mmol/L) | 14.0 ± 0.4            | 13.5 ± 0.5             | 14.8 ± 0.5                            | 14.2 ± 0.5             | 14.2 ± 0.6                       |
| HDL cholesterol (mmol/L)     | 0.3 ± 0.0              | 0.3 ± 0.0              | 0.3 ± 0.0                             | 0.3 ± 0.0              | 0.3 ± 0.0                        |
| LDL cholesterol (mmol/L)     | 2.2 ± 0.1              | 2.2 ± 0.1              | 2.4 ± 0.1                             | 2.2 ± 0.1              | 2.3 ± 0.1                        |
| Triglycerides (mmol/L)    | 0.9 ± 0.1              | 0.7 ± 0.1              | 0.9 ± 0.1                             | 0.8 ± 0.1              | 0.9 ± 0.1                        |
| Tumour necrotic factor-α (pg/mL) | 15.8 ± 1.0           | 15.6 ± 0.9             | 14.4 ± 0.5                            | 14.0 ± 0.7             | 15.1 ± 0.9                       |
| Interleukin-1β (pg/mL)   | 32.0 ± 3.0             | 30.5 ± 1.9             | 271.1 ± 14                            | 28.7 ± 0.8             | 30.5 ± 3.0                       |
| Interleukin-6 (pg/mL)    | 11.9 ± 1.3             | 21.4 ± 6.9             | 11.7 ± 1.3                            | 13.8 ± 2.4             | 12.9 ± 1.4                       |

Data are mean ± SEM.

**Table 2: Daily plasma glucose profile of each group.**

|                         | Control group (n = 20) | Glucose group (n = 20) | Glucose + i-pragliflozin group (n = 20) | Insulin group (n = 21) | Glucose + insulin group (n = 20) |
|-------------------------|------------------------|------------------------|---------------------------------------|------------------------|----------------------------------|
| Day 18                  |                        |                        |                                       |                        |                                  |
| Glucose level (mmol/L)  |                        |                        |                                       |                        |                                  |
| 0 min                   | 11.9 ± 0.5             | 11.7 ± 0.4             | 13.5 ± 0.3                           | 13.0 ± 0.3             | 12.9 ± 0.3                       |
| 15 min                  | 12.3 ± 0.5             | 18.0 ± 0.5             | 16.9 ± 0.4                           | 14.3 ± 0.6             | 21.8 ± 0.8                       |
| 30 min                  | 13.7 ± 0.6             | 15.6 ± 0.7             | 16.1 ± 0.5                           | 15.1 ± 0.4             | 18.9 ± 1.0                       |
| 60 min                  | 12.8 ± 0.7             | 12.4 ± 0.6             | 12.8 ± 0.4                           | 13.5 ± 0.4             | 14.4 ± 0.5                       |
| 120 min                 | 10.6 ± 0.4             | 10.3 ± 0.4             | 10.0 ± 0.2                           | 12.2 ± 0.3             | 11.9 ± 0.3                       |

Glucose level (mmol/L) after second administration

|                         | Control group (n = 21) | Glucose group (n = 22) | Glucose + i-pragliflozin group (n = 22) | Insulin group (n = 17) | Glucose + insulin group (n = 20) |
|-------------------------|------------------------|------------------------|---------------------------------------|------------------------|----------------------------------|
| 0 min                   | 9.9 ± 0.4              | 10.4 ± 0.3             | 10.2 ± 0.4                           | 11.0 ± 0.3             | 11.1 ± 0.2                       |
| 15 min                  | 10.5 ± 0.4             | 17.4 ± 0.4             | 15.4 ± 0.4                           | 11.2 ± 0.3             | 19.3 ± 0.8                       |
| 30 min                  | 11.4 ± 0.5             | 13.6 ± 0.7             | 12.6 ± 0.7                           | 12.7 ± 0.5             | 14.3 ± 1.0                       |
| 60 min                  | 10.5 ± 0.6             | 10.8 ± 0.3             | 9.7 ± 0.3                            | 10.7 ± 0.4             | 11.6 ± 0.3                       |
| 120 min                 | 9.2 ± 0.5              | 8.5 ± 0.2              | 8.8 ± 0.6                            | 10.0 ± 0.4             | 11.0 ± 0.2                       |

Day 102

|                         | Control group (n = 21) | Glucose group (n = 22) | Glucose + i-pragliflozin group (n = 22) | Insulin group (n = 17) | Glucose + insulin group (n = 20) |
|-------------------------|------------------------|------------------------|---------------------------------------|------------------------|----------------------------------|
| 0 min                   | 10.3 ± 0.4             | 10.5 ± 0.5             | 12.3 ± 0.4                           | 11.2 ± 0.2             | 11.6 ± 0.4                       |
| 15 min                  | 10.4 ± 0.6             | 18.0 ± 0.4             | 16.0 ± 0.7                           | 11.8 ± 0.2             | 17.9 ± 0.6                       |
| 30 min                  | 11.3 ± 0.5             | 15.1 ± 0.6             | 14.4 ± 0.7                           | 13.2 ± 0.3             | 15.3 ± 0.5                       |
| 60 min                  | 10.8 ± 0.6             | 12.6 ± 0.6             | 11.8 ± 0.5                           | 11.7 ± 0.3             | 13.0 ± 0.3                       |
| 120 min                 | 10.0 ± 0.2             | 9.6 ± 0.3              | 10.5 ± 0.4                           | 10.9 ± 0.3             | 11.5 ± 0.2                       |

Glucose level (mmol/L) after second administration

|                         | Control group (n = 21) | Glucose group (n = 22) | Glucose + i-pragliflozin group (n = 22) | Insulin group (n = 17) | Glucose + insulin group (n = 20) |
|-------------------------|------------------------|------------------------|---------------------------------------|------------------------|----------------------------------|
| 0 min                   | 8.7 ± 0.3              | 8.8 ± 0.4              | 9.8 ± 0.3                             | 10.8 ± 0.2             | 10.2 ± 0.4                       |
| 15 min                  | 10.4 ± 0.4             | 16.5 ± 0.5             | 15.2 ± 0.8                           | 11.0 ± 0.4             | 18.1 ± 0.8                       |
| 30 min                  | 11.3 ± 0.5             | 12.5 ± 0.6             | 12.7 ± 0.6                           | 12.2 ± 0.4             | 14.4 ± 0.9                       |
| 60 min                  | 10.0 ± 0.4             | 10.9 ± 0.5             | 11.0 ± 0.5                           | 10.8 ± 0.6             | 11.8 ± 0.5                       |
| 120 min                 | 9.2 ± 0.4              | 9.1 ± 0.3              | 9.5 ± 0.3                             | 10.2 ± 0.3             | 10.6 ± 0.3                       |

Data are mean ± SEM. *P < 0.05 versus control, †P < 0.05 versus glucose, ‡P < 0.05 versus i-pragliflozin, and §P < 0.05 versus insulin.

Mice were provided with water (control group, insulin group) or glucose (glucose group, glucose + i-pragliflozin group, and glucose + insulin group) by oral gavage twice a day (9:00 AM: first administration and 4:00 PM: second administration).
Figure 3: Atherosclerotic lesions in each treatment group. (a) Representative histological sections of aortic sinus stained with oil red O at 15 weeks after treatment. The area of oil red O-positive lesions in the aortic wall was evaluated. (b) Representative histological sections of the entire aorta stained with oil red O at 15 weeks after treatment. The area of oil red O-positive lesions in the entire aorta was evaluated. Data are mean ± SEM. *P < 0.05 versus the glucose group by Student’s t-test. C group: control group (n = 21), G group: glucose group (n = 20-21), G + Ipra group: glucose plus ipragliflozin group (n = 22), I group: insulin group (n = 16-17), and G + Ins group: glucose plus insulin group (n = 19-20).
The spike-induced atherosclerotic changes in our model might impact on atherosclerosis. It is possible that the glucose repeated increases in blood glucose levels had only a minor to those recorded in the present study. However, long-term peak levels of temporal hyperglycaemia that were similar enhanced atherosclerosis in apo E-deficient mice [4], with glucose induced by 5-week administration of maltose hyperglycaemia. The aorta of apo E-deficient mice with repetitive hyperglycaemia, and a combination of both did not enhance atherosclerosis in apo E-deficient mice, although repetitive hypoglycaemia increased the death rate. Coincidently, in our model, ipragliflozin suppressed atherosclerosis throughout the aorta of apo E-deficient mice with repetitive hyperglycaemia.

In this study, repetitive hyperglycaemia, repetitive hypoglycaemia, and a combination of both did not enhance atherosclerosis in apo E-deficient mice, although repetitive hypoglycaemia increased the death rate. Coincidently, in our model, ipragliflozin suppressed atherosclerosis throughout the aorta of apo E-deficient mice with repetitive hyperglycaemia.

We reported previously that repeated increases in blood glucose induced by 5-week administration of maltose enhanced atherosclerosis in apo E-deficient mice [4], with peak levels of temporal hyperglycaemia that were similar to those recorded in the present study. However, long-term repeated increases in blood glucose levels had only a minor impact on atherosclerosis. It is possible that the glucose spike-induced atherosclerotic changes in our model might be eventually overwhelmed by concomitant high levels of cholesterol, although the underlying reasons for this effect remain unknown.

To our surprise in the present study, the atherosclerotic areas of the entire aorta were significantly smaller in the glucose plus ipragliflozin group compared with the glucose group. However, because the expression of SGLT2 in rodents is kidney-specific [23], any direct beneficial effects of SGLT2 inhibitors on the vasculature could not be anticipated, raising the possibility of other indirect effects of ipragliflozin on atherosclerosis. First, the inhibitory effects of ipragliflozin on atherosclerosis might simply reflect the glucose-lowering effect of this agent even though the dosage of ipragliflozin used in this study induced only a modest and almost nonsignificant reduction in glucose. Second, ipragliflozin tends to reduce glucose-induced temporal rises in insulin levels, because pharmacological inhibition of SGLT2 enhances urinary glucose excretion and thus reduces blood glucose levels independent of insulin actions [24]. Therefore, it is possible that improvement in temporal hyperinsulinaemia.

### Table 3: Daily plasma insulin profile of each group.

| Day 18 | Control group | Glucose group | Glucose + ipragliflozin group | Insulin group | Glucose + insulin group |
|--------|---------------|---------------|-------------------------------|---------------|-------------------------|
| Insulin level (pmol/L) after first administration | (n = 11) | (n = 11) | (n = 11) | (n = 10) | (n = 11) |
| 0 min | 162.1 ± 22.4 | 143.0 ± 19.0 | 105.1 ± 8.6 | 136.1 ± 12.1 | 93.0 ± 6.9* |
| 15 min | 93.0 ± 10.3 | 291.2 ± 60.3* | 182.6 ± 20.7* | 65.5 ± 1.7* | 211.9 ± 19.0* |
| 30 min | 879.7 ± 10.3 | 146.5 ± 36.2 | 103.4 ± 5.2 | 74.1 ± 8.6* | 1051.1 ± 6.9* |
| 60 min | 1051.2 ± 12.1 | 91.3 ± 17.2 | 65.5 ± 5.2* | 77.5 ± 6.9 | 68.9 ± 5.2 |
| 120 min | 1172.2 ± 8.6 | 94.8 ± 17.2 | 74.1 ± 6.9* | 82.7 ± 8.6 | 87.9 ± 8.6 |

| Day 102 | (n = 11) | (n = 11) | (n = 11) | (n = 8) | (n = 10) |
|--------|---------------|---------------|-------------------------------|---------------|---------|
| Insulin level (pmol/L) after first administration | (n = 11) | (n = 11) | (n = 11) | (n = 10) | (n = 11) |
| 0 min | 163.7 ± 24.1 | 144.7 ± 15.5 | 144.7 ± 19.0 | 110.3 ± 15.5 | 96.5 ± 6.9 |
| 15 min | 98.2 ± 10.3 | 291.2 ± 37.9* | 253.3 ± 24.1* | 81.0 ± 6.9* | 241.2 ± 19.0* |
| 30 min | 86.2 ± 6.9 | 124.1 ± 12.1 | 117.2 ± 12.1 | 82.7 ± 6.9 | 112.0 ± 6.9 |
| 60 min | 86.2 ± 8.6 | 103.4 ± 6.9 | 74.1 ± 5.2 | 87.9 ± 10.3 | 84.4 ± 6.9 |
| 120 min | 99.9 ± 20.7 | 101.7 ± 6.9 | 82.7 ± 10.3 | 94.8 ± 10.3 | 84.4 ± 8.6 |

| Insulin level (pmol/L) after second administration | (n = 11) | (n = 11) | (n = 11) | (n = 10) | (n = 11) |
|--------|---------------|---------------|-------------------------------|---------------|---------|
| 0 min | 1172.2 ± 19.0 | 124.1 ± 12.1 | 98.2 ± 10.3 | 130.9 ± 24.1 | 122.3 ± 15.5 |
| 15 min | 99.9 ± 8.6 | 398.0 ± 24.1* | 274.0 ± 24.1* | 84.4 ± 10.3 | 286.0 ± 29.3* |
| 30 min | 103.4 ± 12.1 | 141.3 ± 19.0 | 106.8 ± 6.9 | 101.7 ± 10.3 | 134.4 ± 20.7 |
| 60 min | 74.1 ± 6.9 | 101.7 ± 10.3 | 81.0 ± 8.6 | 84.4 ± 10.3 | 93.0 ± 8.6 |
| 120 min | 79.3 ± 10.3 | 87.9 ± 8.6 | 77.5 ± 8.6 | 101.7 ± 10.3 | 91.3 ± 12.1 |

Data are mean ± SEM. *P < 0.05 versus control, †P < 0.05 versus glucose, ‡P < 0.05 versus ipragliflozin, and ‡P < 0.05 versus insulin. Mice were provided with water (control group, insulin group) or glucose (glucose group, glucose + ipragliflozin group, and glucose + insulin group) by oral gavage twice a day (9:00 AM: first administration and 4:00 PM: second administration).

**4. Discussion**

In this study, repetitive hyperglycaemia, repetitive hypoglycaemia, and a combination of both did not enhance atherosclerosis in apo E-deficient mice, although repetitive hypoglycaemia increased the death rate. Coincidently, in our model, ipragliflozin suppressed atherosclerosis throughout the aorta of apo E-deficient mice with repetitive hyperglycaemia.

We reported previously that repeated increases in blood glucose induced by 5-week administration of maltose enhanced atherosclerosis in apo E-deficient mice [4], with peak levels of temporal hyperglycaemia that were similar to those recorded in the present study. However, long-term repeated increases in blood glucose levels had only a minor impact on atherosclerosis. It is possible that the glucose spike-induced atherosclerotic changes in our model might be eventually overwhelmed by concomitant high levels of cholesterol, although the underlying reasons for this effect remain unknown.
was associated with reductions in atherogenesis in our model. Although we demonstrated previously that temporal hyperglycaemia, but not temporal hyperinsulinaemia, induced monocyte adhesion to endothelial cells in rats [3, 25], temporal hyperinsulinaemia could probably indirectly promote atherosclerosis through unknown mechanism. Finally, SGLT-2 inhibitors also act as osmotic diuretics, resulting in lower blood pressure alongside the glucose-lowering effect [26]. These effects potentially contributed to the prevention of atherosclerosis observed herein.

On the other hand, random plasma glucose levels modestly but significantly increased from baseline on days 12 and 102, but not days 22 and 92, in the glucose plus ipragliflozin group. These factors may attenuate the favourable effect of ipragliflozin on the progression of atherosclerosis. Since the exact reasons for these unexpected results are largely unknown, evaluation of the possible metabolism-related factors, such as hepatic glucose production and plasma glucose levels, should be addressed in future studies.

Recent studies showed that hypoglycaemia is associated with increased mortality from CVD and other causes [11, 27, 28]. The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study demonstrated a small but significant inverse relationship between the number of hypoglycaemic events and the risk of death in the intensive treatment group [27]. In the same study, higher HbA1c levels in the intensive treatment group were also associated with increased mortality [29]. On the other hand, the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) showed that severe hypoglycaemia was also shown to be associated with increased mortality [28]. However, in the same study, the mortality rates were lower among subjects who experienced severe hypoglycaemia in the intensive treatment group than those in the standard group in that study, while severe hypoglycaemia was more frequent in the intensive treatment group [30]. Taking these results into consideration, it may be important to achieve appropriate glycaemic control without increased hypoglycaemic events in order to reduce mortality in the management of diabetes. In the present study, mice of the insulin group had the highest death rate, followed by those of the glucose plus insulin group. Because hypoglycaemia became milder at the end of our study in the glucose plus insulin group compared to the insulin group, the death rate was seemingly largely dependent on the severity of hypoglycaemia. However, the atherosclerotic lesions in the insulin group were not expanded, suggesting that hypoglycaemia-related death was not associated with events caused by advanced atherosclerosis, at least under the context of this experiment. On the other hand, we demonstrated previously that repetitive hypoglycaemia promoted the initial stage of atherosclerosis [18] and neointima formation after vascular injury in GK rats [19]. The exact reason for such discrepancy is not clear at present, but it could reflect differences in the stage of atherosclerosis, species, and the levels of cholesterol in diabetic and nondiabetic models.

What are the factors associated with death during hypoglycaemia? One possibility was raised by results showing that hypoglycaemia was associated with electrocardiographic changes, wherein severe hypoglycaemic events were significantly associated with prolonged corrected QT in patients with type 1 diabetes, reflecting abnormalities in ventricular myocardial repolarisation [31]. Notably, such arrhythmogenic effects that were induced, at least in part, by hypoglycaemia

Table 4: Plasma glucose levels after intraperitoneal injection of saline or insulin in each group.

| Day 22 | Control group (n = 11) | Glucose group (n = 10) | Glucose + ipragliflozin group (n = 11) | Insulin group (n = 11) | Glucose + insulin group (n = 11) |
|--------|------------------------|------------------------|---------------------------------------|------------------------|---------------------------------|
| Glucose level (mmol/L) after administration | | | | | |
| 0 min  | 9.4 ± 0.2              | 9.5 ± 0.2              | 10.2 ± 0.3                           | 9.7 ± 0.2              | 10.0 ± 0.3                      |
| 15 min | 9.4 ± 0.4              | 17.2 ± 0.7*            | 15.2 ± 0.5*                          | 5.5 ± 0.2**            | 7.0 ± 0.2**                      |
| 30 min | 11.6 ± 0.4             | 14.8 ± 1.0*            | 14.6 ± 0.4*                          | 5.0 ± 0.2**            | 5.1 ± 0.2**                      |
| 45 min | 12.6 ± 0.6             | 13.0 ± 0.7             | 13.3 ± 0.4                           | 4.8 ± 0.2**            | 5.0 ± 0.2**                      |
| 60 min | 12.5 ± 0.4             | 12.8 ± 0.8             | 13.0 ± 0.3                           | 4.3 ± 0.3**            | 4.4 ± 0.2**                      |
| 90 min | 11.5 ± 0.3             | 11.9 ± 0.6             | 10.8 ± 0.3                           | 3.5 ± 0.5**            | 3.1 ± 0.2**                      |
| Day 92 | (n = 11)               | (n = 10)               | (n = 11)                              | (n = 11)               | (n = 10)                         |
| Glucose level (mmol/L) after administration | | | | | |
| 0 min  | 8.8 ± 0.1              | 9.1 ± 0.2              | 8.6 ± 0.3                            | 8.9 ± 0.2              | 9.0 ± 0.2                        |
| 15 min | 10.2 ± 0.4             | 16.9 ± 0.9*            | 14.2 ± 0.8**                         | 5.2 ± 0.2**            | 8.7 ± 1.1**                      |
| 30 min | 11.4 ± 0.4             | 14.7 ± 0.7*            | 12.5 ± 0.8                           | 4.7 ± 0.2**            | 6.0 ± 0.7**                      |
| 45 min | 12.6 ± 0.3             | 13.5 ± 0.7             | 12.0 ± 0.7                           | 4.4 ± 0.2**            | 5.9 ± 1.1**                      |
| 60 min | 12.9 ± 0.6             | 14.2 ± 0.8             | 12.1 ± 0.7                           | 3.8 ± 0.2**            | 5.8 ± 1.3**                      |
| 90 min | 11.6 ± 0.5             | 12.4 ± 0.6             | 10.2 ± 0.7                           | 3.2 ± 0.6**            | 4.5 ± 1.1**                      |

Data are mean ± SEM. *P < 0.05 versus control, †P < 0.05 versus glucose, ‡P < 0.05 versus ipragliflozin, and ¶P < 0.05 versus insulin. Mice received intraperitoneal injections of 10 mL/kg saline (control group, glucose group, and glucose + ipragliflozin group) or injections of 8 IU/kg insulin (insulin group and glucose + insulin group).
through the lowering of serum potassium or augmentation of sympathetic nerve activity could be life threatening. In addition, hypoglycaemia is known to induce platelet aggregation and inflammation [28], changes that could potentially increase plaque vulnerability without the associated progression of atherosclerosis. These findings emphasize the need for further experiments to address this issue, especially using mice models of plaque rupture [32].

The present study has certain limitations. First, we used higher dosage of insulin than those for the treatment of the patients with T2DM. The main reason was that those dosages were required in order to induce hypoglycaemia. Second, we did not measure serum and urinary levels of counter regulatory hormones during hypoglycaemia. Third, in this study, we evaluated only a few inflammatory cytokines. Thus, measurement of other cytokines is probably needed in the future studies. Forth, we could not evaluate the effect of insulin injection on proliferative potential [33].

In conclusion, our data suggested that long-term glucose fluctuations, including repetitive postprandial glucose spikes, repetitive hypoglycaemia, and combinations thereof, have little effect on atherogenesis. In addition, the low survival rate with repetitive hypoglycaemia is not necessarily associated with increased atherosclerotic plaques.

**Abbreviations**

ACCORD: Action to Control Cardiovascular Risk in Diabetes

ADVANCE: Action in Diabetes and Vascular Disease; Preterax and DiaMicon Modified Release Controlled Evaluation

apo: Apolipoprotein

BW: Body weight

CVD: Cardiovascular disease

GK rat: Goto-Kakizaki rat

SGLT2: Sodium-glucose cotransporter 2

SMCs: Smooth muscle cells

T2DM: Type 2 diabetes mellitus

**Conflict of Interests**

Tomoya Mita received research funds from MSD and Takeda Pharma K.K. and has received lecture fees from AstraZeneca K.K., Boehringer Ingelheim, Eli Lilly, Kowa Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., MSD, Ono Pharmaceutical Co., and Takeda Pharmaceutical Co. Toshiyuki Takasu is an employee of Astellas Pharma Inc. Yoshio Fujitani has received lecture fees from Novartis Pharmaceuticals and Eli Lilly and research funds from Novartis Pharmaceuticals, MSD, and Takeda Pharmaceutical Co. Hirotaka Watada has received lecture fees from Novo Nordisk, Inc., Eli Lilly and Company, Sanofi, Dainippon Sumitomo Pharma Co., Fujifilm, Bayer Health Care, Kissei Pharmaceutical Company, Mochida Pharmaceutical Company, MSD, Takeda Pharmaceutical Company, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi-Sankyo, Ono Pharmaceutical Co., Ltd., Novartis Pharmaceuticals Corporation, Mitsubishi Tanabe Pharma Corporation, AstraZeneca LP, Kyowa Hakko Kirin Company, Ltd., Sanwa Kagaku Kenkyusyo Company, Ltd., Kowa Company Ltd., and Astellas Pharma, Inc., advisory fees from Novo Nordisk, Inc., Mochida Pharma Company, AstraZeneca LP, Kowa Company, Astellas Pharma, Inc., Sanofi, Boehringer Ingelheim Pharmaceuticals, Inc., MSD, Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Dainippon Sumitomo Pharma Co., Takeda Pharmaceutical Company, Ono Pharmaceutical Co., Pfizer, Inc., Kowa Company, and research funds from Boehringer Ingelheim, Pfizer, Mochida Pharmaceutical Co., Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Sanwakagaku Kenkyusho, Terumo Corp., Eli Lilly, Mitsubishi Tanabe Pharma, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Shionogi, Pharma, Dainippon Sumitomo Pharma, Kissei Pharma, and AstraZeneca.

**Acknowledgments**

The authors thank Mrs. Naoko Daimaru, Eriko Magoshi, Kiyomi Nakamura, and Hiroko Tsujimura for the excellent technical assistance. This paper is funded by a research grant from Astellas Pharma Inc. The funding source advised the study design and collaborated with the authors in data interpretation and writing of the report.

**References**

[1] The DECODE Study Group on Behalf of the European Diabetes Epidemiology Group, “Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria,” *The Lancet*, vol. 354, no. 9179, pp. 617–621, 1999.

[2] T. Nakagami, “Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin,” *Diabetologia*, vol. 47, no. 3, pp. 385–394, 2004.

[3] A. Otsuka, K. Azuma, T. Iesaki et al., “Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta,” *Diabetologia*, vol. 48, no. 12, pp. 2667–2674, 2005.

[4] T. Mita, A. Otsuka, K. Azuma et al., “Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice,” *Biochemical and Biophysical Research Communications*, vol. 358, no. 3, pp. 679–685, 2007.

[5] L. Quagliaro, L. Piconi, R. Assaloni, L. Martinelli, E. Motz, and A. Ceriello, “Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation,” *Diabetes*, vol. 52, no. 11, pp. 2795–2804, 2003.

[6] A. Ceriello, K. Esposito, L. Piconi et al., “Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients,” *Diabetes*, vol. 57, no. 5, pp. 1349–1354, 2008.

[7] I. Raz, G. Jermendy, P. W. F. Wilson et al., “Effects of prandial versus fasting glyceria on cardiovascular outcomes in type 2 diabetes: the HEART2D trial,” *Diabetes Care*, vol. 32, no. 3, pp. 381–386, 2009.

[8] A. Patel, S. MacMahon, J. Chalmers et al., “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” *The New England Journal of Medicine*, vol. 358, no. 24, pp. 2560–2572, 2008.
[9] W. Duckworth, C. Abraira, T. Moritz et al., “Glucose control and vascular complications in veterans with type 2 diabetes,” The New England Journal of Medicine, vol. 360, no. 2, pp. 129–139, 2009.

[10] H. C. Gerstein, M. E. Miller, R. P. Byington et al., “Effects of intensive glucose lowering in type 2 diabetes,” The New England Journal of Medicine, vol. 358, pp. 2545–2559, 2008.

[11] K. Khunti, M. Davies, A. Majeed, B. L. Thorsted, M. L. Wolden, and S. K. Paul, “Hypoglycaemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study,” Diabetes Care, vol. 38, no. 2, pp. 316–322, 2015.

[12] B. M. Frier, R. J. M. Corrall, N. M. Davidson, R. G. Webber, A. Dewar, and E. B. French, “Peripheral blood cell changes in response to acute hypoglycaemia in man,” European Journal of Clinical Investigation, vol. 13, no. 1, pp. 33–39, 1983.

[13] A. Collier, A. W. Patrick, D. A. Hepburn et al., “Leucocyte mobilization and release of neutrophil elastase following acute insulin-induced hypoglycaemia in normal humans,” Diabetic Medicine, vol. 7, no. 6, pp. 506–509, 1990.

[14] P. J. Galloway, G. A. Thomson, B. M. Fisher, and C. G. Semple, “Insulin-induced hypoglycaemia induces a rise in C-reactive protein,” Diabetes Care, vol. 23, no. 6, pp. 861–862, 2000.

[15] A. E. Kitabchi, G. E. Umpierrez, J. M. Miles, and J. N. Fisher, “Hyperglycemic crises in adult patients with diabetes,” Diabetes Care, vol. 32, no. 7, pp. 1335–1343, 2009.

[16] J. Dalsgaard-Nielsen, S. Madsbad, and J. Hilsted, “Changes in platelet function, blood coagulation and fibrinolysis during insulin-induced hypoglycaemia in juvenile diabetics and normal subjects,” Thrombosis and Haemostasis, vol. 47, no. 3, pp. 254–258, 1982.

[17] B. M. Fisher, D. A. Hepburn, J. G. Smith, and B. M. Frier, “Responses of peripheral blood cells to acute insulin-induced hypoglycaemia in humans: effect of alpha-adrenergic blockade,” Hormone and Metabolic Research, Supplement, supplement 26, pp. 109–110, 1992.

[18] W. L. Jin, K. Azuma, T. Mita et al., “Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta,” Diabetologia, vol. 54, no. 7, pp. 1921–1929, 2011.

[19] E. Yasunari, T. Mita, Y. Oso noi et al., “Repetitive hypoglycemia increases circulating adrenaline level with resultant worsening of intimal thickening after vascular injury in male goto-kakizaki rat carotid artery,” Endocrinology, vol. 155, no. 6, pp. 2244–2253, 2014.

[20] M. Arakawa, T. Mita, K. Azuma et al., “Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4,” Diabetes, vol. 59, no. 4, pp. 1030–1037, 2010.

[21] T. Mita, H. Goto, K. Azuma et al., “Impact of insulin resistance on enhanced monocyte adhesion to endothelial cells and atherosclerogenesis independent of LDL cholesterol level,” Biochemical and Biophysical Research Communications, vol. 395, no. 4, pp. 477–483, 2010.

[22] N. Ervina, T. Mita, E. Yasunari et al., “Anaglptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice,” Endocrinology, vol. 154, no. 3, pp. 1260–1270, 2013.

[23] I. Sabolic, I. Vrhovac, D. B. Eror et al., “Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences,” The American Journal of Physiology Cell physiology: Cell Physiology, vol. 302, pp. 117–1188, 2012.

[24] F. M. Hasan, M. Alsahl, and J. E. Gerich, “SGLT2 inhibitors in the treatment of type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 104, no. 3, pp. 297–322, 2014.

[25] A. Tanaka, K. Azuma, Y. Toyofuku et al., “Insulin and nateglinide reduce monocyte adhesion to endothelial cells in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation,” Biochemical and Biophysical Research Communications, vol. 350, no. 1, pp. 195–201, 2006.

[26] R. V. Oliva and G. L. Bakris, “Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors,” Journal of the American Society of Hypertension, vol. 8, no. 5, pp. 330–339, 2014.

[27] E. R. Seaquist, M. E. Miller, D. E. Bonds et al., “The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study,” Diabetes Care, vol. 35, no. 2, pp. 409–414, 2012.

[28] S. Zoungas, A. Patel, J. Chalmers et al., “Severe hypoglycemia and risks of vascular events and death,” The New England Journal of Medicine, vol. 363, no. 15, pp. 1410–1418, 2010.

[29] D. E. Bonds, M. E. Miller, R. M. Bergenstal et al., “The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study,” British Medical Journal, vol. 340, Article ID b4909, 2010.

[30] P. Hamet, “What matters in ADVANCE and ADVANCE-ON,” Diabetes, Obesity & Metabolism, vol. 14, supplement 1, pp. 20–29, 2012.

[31] G. Gruden, S. Giunti, F. Barutta et al., “QTc interval prolongation is independently associated with severe hypoglycem ic attacks in type 1 diabetes from the EURODIAB IDDM complications study,” Diabetes Care, vol. 35, no. 1, pp. 125–127, 2012.

[32] T. Matoba, K. Sato, and K. Egashira, “Mouse models of plaque rupture,” Current Opinion in Lipidology, vol. 24, no. 5, pp. 419–425, 2013.

[33] H. Sugimoto, D. J. Franks, L. Leca valier, J.-L. Chiasson, and P. Hamet, “Therapeutic modulation of growth-promoting activity in platelets from diabetics,” Diabetes, vol. 36, no. 5, pp. 667–672, 1987.